Compare Ristia Bintang Mahkotasejati Tbk. (RBMS) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ristia Bintang Mahkotasejati Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Ristia Bintang Mahkotasejati Tbk. trades at Rp63 (market cap 162.03B, 15.21M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Ristia Bintang Mahkotasejati Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.
| RBMS | SCPI | |
|---|---|---|
Market Cap | 162.03B | 104.4B |
Volume | 15.21M | — |
Lot | 152.08K | — |
Turnover | 946.82M | — |
Average Price | 62.26 | — |
Value | 946.82M | — |
Indicative Equilibrium Price | 63 | — |
Indicative Equilibrium Volume | 5.97K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ristia Bintang Mahkotasejati Tbk.
PT Ristia Bintang Mahkotasejati Tbk (the Company) was established based on the Notarial Deed No. 114 of Lieke Lianadevi Tukgali, S.H., dated May 22, 1985. PT. Ristia Bintang Mahkotasejati is a Real Estate developer and contractor. A company developing houses, store houses and also facilities supported in Bekasi, Tanggerang and Karawang.
Read more on RBMS →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
